Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma

Vanessa Klapp; Lorenzo Galluzzi

doi:10.1016/j.trecan.2021.11.006

Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma

Trends Cancer. 2022 Jan;8(1):1-3. doi: 10.1016/j.trecan.2021.11.006. Epub 2021 Nov 25.

Authors

Vanessa Klapp¹, Lorenzo Galluzzi²

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
² Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA. Electronic address: deadoc80@gmail.com.

PMID: 34840109
DOI: 10.1016/j.trecan.2021.11.006

Abstract

Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.

Keywords: CGAS; PARP inhibitors; VEGFA; autophagy; immune checkpoint inhibitors; venetoclax.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

BRCA1 Protein / genetics
Homologous Recombination
Humans
Immunization
Ovarian Neoplasms* / genetics
Ovarian Neoplasms* / pathology
Ovarian Neoplasms* / therapy

Substances

BRCA1 Protein
BRCA1 protein, human